International Journal of Medical Science and Clinical Invention 13(01): 7830-7840, 2026
DOI:10.18535/ijmsci/v13i.02.01
https://valleyinternational.net/index.php/ijmsci

Cutaneous Malignancies: An Integrated Review of Epidemiology, Clinical Classification, and the Transition from Carcinogenesis to Multidisciplinary Prevention

Umesh C. Gupta[1] and Subhas C. Gupta[2]

1. Emeritus Research Scientist, Agriculture and Agri-Food Canada, Charlottetown Research and Development Centre, Charlottetown, PE, C1A4N6 Canada.
2. Chairman and Professor, The Department of Plastic Surgery, Loma Linda University School of Medicine, Loma Linda, California, 92354 USA.

Abstract

Skin cancer represents a formidable and escalating challenge to global public health systems, driven by aging populations and increasing environmental exposure. It is a widespread malignancy resulting from uncontrolled cell proliferation, primarily triggered by ultraviolet (UV) radiation-induced DNA damage. While basal cell carcinoma and squamous cell carcinoma are the most common forms, melanoma remains the most lethal due to its rapid metastasis, and Merkel cell carcinoma represents a rare but aggressive neuroendocrine variant. Despite high incidence rates, the prognosis for cutaneous malignancies is favorable with early detection. This review integrates epidemiological data with clinical classification and management strategies. Preventive measures extend beyond traditional photoprotection to include lifestyle modifications, the use of chemical peels for actinic keratosis, and dietary phytochemicals that leverage epigenetic mechanisms to reverse procarcinogenic actions. Furthermore, the therapeutic landscape has evolved from surgical excision to include advanced immunotherapies, such as immune checkpoint inhibitors, and the application of nanomedicine for targeted drug delivery and high-resolution imaging. A multidisciplinary approach combining prevention, early diagnosis via advanced imaging, and personalized therapeutics is essential for reducing the global burden of these diseases.

Keywords: Cutaneous malignancies, Melanoma, Chemoprevention, Immunotherapy, Nanomedicine, Ultraviolet radiation, Preventative measures

1. Introduction: The Global Burden of Cutaneous Malignancy

Skin cancer represents a formidable and escalating challenge to global public health systems, manifesting as a "silent epidemic" driven by aging populations, changing environmental conditions, and lifestyle factors [1].

As the largest organ of the human body, the skin serves as the primary interface between the internal physiological environment and external stressors, providing a critical line of defense against exogenous biological and non-biological agents [2]. However, this barrier function exposes the skin to continuous environmental assaults, most notably ultraviolet (UV) radiation, which is the preeminent environmental carcinogen responsible for most cutaneous malignancies [3, 4].

The incidence of skin cancer has reached epidemic proportions globally. It stands as the most common group of malignancies in the United States, with current data indicating that more than five million individuals are treated for the disease annually [5]. The statistical projections are equally alarming, with estimates suggesting that 20% of Americans will develop some form of skin cancer by the age of 70 [5]. This trend signifies a substantial burden on healthcare infrastructure, necessitating a shift from reactive treatment to proactive prevention and early detection.

This rising trend is not confined to the United States; similar patterns are observed internationally, particularly in nations with significant Caucasian populations and high insolation levels. Skin cancer represents one of the most prevalent dermatologic malignancies, with both incidence and mortality continuing to rise annually. Marked geographic heterogeneity exists, with the highest incidence rates reported in Oceania, followed by North America and Europe [6]. Australia consistently demonstrates the greatest disease burden, whereas substantially lower incidence rates are observed across Africa and Asia. Global estimates from 2022 indicate that more than 330,000 individuals were newly diagnosed with melanoma, with nearly 59,000 associated deaths. Collectively, these data underscore skin cancer as a significant and persistent global health challenge, characterized by pronounced regional and national disparities [6].

Gender disparities are also evident in the Canadian data; approximately 1,300 Canadians are diagnosed with melanoma annually, with men comprising most cases. Furthermore, the anatomical distribution of tumors varies by sex: in women, melanomas tend to develop on the extremities, whereas in men, they are more frequently found on the trunk, head, or neck [7].

The burden of disease is particularly pronounced in the Southern Hemisphere. New Zealand reports over 90,000 new diagnoses annually, a staggeringly high per capita rate [8]. This disproportionate incidence, significantly exceeding rates in comparable Northern Hemisphere latitudes, is attributed to unique atmospheric and astronomical conditions. Due to the elliptical nature of Earth's orbit, the Southern Hemisphere is physically closer to the sun during its summer months compared to the Northern Hemisphere summer. This proximity results in peak UV radiation levels that are approximately 40% higher in New Zealand than at equivalent latitudes in the north, creating an environment of extreme carcinogenic potential [8].

Despite these daunting statistics, the prognosis for skin cancer is highly favorable when detected early. Over 95% of skin cancers are treatable if diagnosed at an incipient stage [1]. This stark contrast between high incidence and high treatability underscores the paramount importance of public awareness, early diagnosis, and the implementation of robust preventive strategies.

2. Historical Evolution of Medical Understanding

The history of skin cancer medicine is a testament to our collective evolving comprehension of pathology, moving from visual observation to molecular intervention.

2.1 Ancient Origins and Nomenclature

The earliest recorded interactions with skin cancer date back to antiquity. The terminology that underpins modern oncology, "carcinoma" and "karkino", was coined by Hippocrates (460-375 BC), widely revered as the father of medicine [9]. Hippocrates used these terms, derived from the Greek word for crab, to describe the way blood vessels radiating from a malignant tumor resembled the legs of a crab. His observations laid the foundational distinction between benign and malignant growths, acknowledging the invasive and destructive nature of the latter. Following Hippocrates, the Greek physician Rufus of Ephesus (60-120 AD) continued to refine these descriptions, contributing to the early semiology of cutaneous tumors [9].

Paleopathological evidence further confirms the ancient presence of these diseases. Examinations of mummies from the 4th century BC in Peru have revealed diffuse metastasis in skull bones and rounded melanotic masses in the skin, indicating that melanoma plagued human populations long before the modern ozone depletion [9].

2.2 The 19th Century: Defining Melanoma

The distinct identification of "melanoma" as a specific pathological entity occurred in the 19th century. The French physician René Laennec, famous for inventing the stethoscope, discussed "la melanoses" in his unpublished works, referencing the characteristic black pigmentation of the tumors [9]. In 1820, Norris provided early insights into the genetic basis of melanoma, observing its occurrence within families, and in 1838, Robert Carswell officially utilized the medical term "melanoma" to describe pigmented malignant lesions of the skin [9].

2.3 Therapeutic Evolution

For centuries, the treatment of these lesions was rudimentary. In the 1800s, treatments such as bloodletting, laxatives, and dietary modifications were standard, mirroring therapies that had been used since the era of Hippocrates [10]. It was not until the 16th century that surgery began to be developed as a viable treatment for cancer. The discovery of anesthesia in the 1840s marked a turning point, significantly improving the prognosis for surgical interventions by allowing for more extensive and precise excisions [10].

The 20th century brought a deeper understanding of etiology and refined treatments. The link between UV radiation and skin cancer began to be scientifically established, leading to the commercial availability of sunscreen in 1928 [10]. In the 1930s, Dr. Frederic Mohs established Mohs micrographic surgery, a technique that involves layer-by-layer removal of tissue with immediate microscopic examination. This method remains the gold standard for high-risk non-melanoma skin cancers due to its high cure rates and tissue conservation [10].

2.4 The Modern Era

The most recent historical epoch is defined by the advent of immunotherapy and personalized medicine. Recent presentations at major annual oncological forums, such as the American Society of Clinical Oncology (ASCO) Congress, have highlighted breakthrough combinations of standard immunotherapy with RNA vaccines, showing significant improvements in recurrence rates for high-risk cancers [7].

3. Etiology and Pathogenesis: The Interaction of Environment and Biology

Skin cancer develops when skin cells undergo uncontrolled proliferation due to DNA damage. While the specific mutations vary by cancer type, the underlying drivers are a combination of environmental insults and intrinsic susceptibility.

3.1 Ultraviolet Radiation: The Primary Carcinogen

The sun provides life-sustaining energy, but its ultraviolet (UV) radiation is the single most significant environmental factor in the pathogenesis of skin cancer. UV radiation is an established human carcinogen that inflicts damage on deoxyribonucleic acid (DNA) [3]. This damage can be direct, where UV photons are absorbed by DNA bases causing structural distortions (dimers), or indirect, through the generation of reactive oxygen species (ROS) that cause oxidative stress [4].

Mechanism of Damage: DNA damage can occur years prior to the clinical manifestation of cancer. It is often the result of cumulative insults of short periods of intense exposure (sunburns) or long-term chronic exposure [11].

Artificial UV Sources: The risk is not limited to natural sunlight. Non-natural sources, such as tanning beds and sunlamps, deliver concentrated doses of UV radiation and are potent contributors to carcinogenesis. Their use is strongly linked to early-onset skin cancer, particularly in younger demographics [12].

3.2 Genetic and Host Factors

Pigmentation and Phototype: Ethnicity and skin color are primary determinants of risk. Melanin acts as a natural sunscreen; thus, individuals with fair skin, light hair, and light-colored eyes possess lower melanin protection and are at significantly greater risk [13]. These individuals burn easily, a sign of acute DNA injury. Conversely, while skin cancer is less common in people with brown or black skin, it is often diagnosed at later stages, sometimes in "hidden" areas [14].

Heredity*:* A family history of skin cancer significantly elevates risk, suggesting a genetic predisposition. Inherited mutations can impair DNA repair mechanisms or cell cycle control [11].

Immunosuppression*:* The immune system plays a vital role in tumor surveillance. Individuals with deteriorated immune systems, such as those with HIV/AIDS or those taking immunosuppressive drugs for organ transplants, are at a much higher risk of developing aggressive skin cancers [12].

3.3. Chemical and Viral Carcinogenesis

Exposure to certain chemical agents acts as a risk factor. Contact with arsenic, coal tar, soot, and petroleum products has been associated with higher cancer rates [12]. Additionally, viral infections, specifically certain strains of the human papillomavirus (HPV), are linked to the development of squamous cell carcinoma [12].

3.4. Molecular Mechanisms

Skin cancer is characterized by molecular changes, the evolution of inherited DNA and/or ribonucleic acid (RNA) over time, which impact proteins and signaling pathways [15]. Recent research has also illuminated the "molecular crosstalk" between dietary polyphenols and gut microbiota as a potential pathway for cancer prevention, suggesting that systemic metabolic health influences cutaneous carcinogenesis [16].

4. Clinical Classification and Symptomatology

Cutaneous neoplasms are heterogeneous. While more than 100 types of tumors are found on the skin, they are principally divided into three main categories: Basal Cell Carcinoma (BCC), Squamous Cell Carcinoma (SCC), and Melanoma [17].

4.1 Basal Cell Carcinoma (BCC)

BCC is the most common form of skin cancer. It arises from the basal cells in the deepest layer of the epidermis.

Clinical Presentation: On fair skin, BCC frequently presents as a skin-colored or pink bump, often pearly in appearance. On brown or black skin, the presentation can be different, appearing as a glossy black bump with a rolled border [14].

Other Signs: It may also manifest as a persistent, non-healing sore, a reddish patch, or a scar-like area. A key characteristic is fragility; these lesions bleed easily after minor injuries or shaving [14].

Distribution: It predominantly occurs in sun-exposed areas such as the face, head, neck, and arms, though it can appear elsewhere [15].

Prognosis: BCC grows slowly and rarely metastasizes, leading to a generally good prognosis if treated early [17].

4.2 Squamous Cell Carcinoma (SCC)

SCC originates in the squamous cells that make up the middle and outer layers of the skin.

Clinical Presentation: Symptoms characteristically appear as a rough or scaly red patch with irregular borders or a firm, raised lump. The lump may have a central depression or ulceration [14].

Other Signs: Lesions may be crusty, bleed easily, or have a wart-like appearance. They often present as sores that heal and then return [18].

Distribution: In fair-skinned individuals, SCC is found on sun-exposed regions (face, lower lips, ears, neck, hands). In black or darker skin, it is more likely to occur in less sun-exposed areas, such as the palms, soles, or under the nails [18].

Prognosis: SCC is more aggressive than BCC and has a higher potential for metastasis, but early detection yields a good prognosis [17].

4.3 Melanoma

Melanoma is the most dangerous form of skin cancer. It originates from melanocytes, the pigment-producing cells.

Nature: It is categorized by rapid growth and early metastasis. Its incidence has been increasing, mainly attributed to increased UV radiation exposure [19].

Clinical Presentation: Initial symptoms often involve a change in an existing mole or the development of a new, unusual-looking pigmented growth. Crucially, it does not always begin as a mole; it can arise on healthy skin [20].

Diagnostic Signs: The "ABCDE" rule is implied: **a**symmetry, irregular **b**orders, changes in **c**olor, increasing **d**iameter, and **e**volving symptoms (itching, bleeding, crusting) [20].

Distribution: Common sites include the arms, back, face, and legs. However, hidden melanomas can occur in areas not exposed to the sun, such as the soles of the feet, palms, and fingernail beds. This presentation is particularly common in people with brown or black skin [20].

4.4 Merkel Cell Carcinoma (MCC)

MCC is a rare, aggressive neuroendocrine carcinoma.

Origin: It originates in Merkel cells found in the epidermis.

Clinical Presentation: It typically appears as a painless, firm, shiny bump (red, pink, or blue) on the face, head, or neck [21].

Risk Profile: It chiefly affects older people (>50 years), particularly fair-skinned Caucasians. It is associated with a weakened immune system and exposure to the Merkel cell polyomavirus [22].

Prognosis: MCC exhibits aggressive behavior with a high recurrence rate and a propensity for early metastasis to lymph nodes and other organs. Despite improvements in therapy, the prognosis remains poor compared to other skin cancers [23].

Table 1: Comparative Analysis of Major Skin Cancer Types

Feature	**Basal Cell Carcinoma (BCC)**	**Squamous Cell Carcinoma (SCC)**	**Melanoma**

Origin Cell	Basal cells (Epidermis)	Squamous cells (Epidermis)	Melanocytes (Pigment cells)
Common Presentation	Pink/pearly bump or non-healing sore. Rolled borders.	Rough, scaly red patch or wart-like growth.	New/changing pigmented mole. Asymmetrical.
Growth Rate	Slow	Moderate	Fast/Rapid
Metastasis Risk	Very Low	Moderate	High (Early metastasis)
Primary Locations	Sun-exposed (Face, Neck)	Sun-exposed (Face, Ears, Hands)	Legs, Back, Trunk (Anywhere)
Key Risk Group	Fair skin, chronic sun exposure	Fair skin, HPV, Immunosuppressed	History of sunburns, many moles

5. Diagnostic Modalities: Imaging and Technology

Accurate diagnosis, staging, and monitoring are pivotal for effective management. While visual inspection remains the primary screening tool, advanced technologies are enhancing precision.

5.1 Visual and Physical Examination

The standard approach involves a visual check for new growth or changes in existing spots. The "ugly duckling" sign, a mole that looks different from others, is a key indicator. General symptoms for all types include skin lumps that grow slowly, do not resolve, or sores that bleed and form scabs [14].

5.2 Ultrasound and Imaging

Imaging technologies are constantly being developed to improve diagnosis and treatment planning.

High-Frequency Ultrasound: This non-invasive technique uses sound waves to provide structural information about the tumor. It offers anatomical details regarding depth and margins that cannot be inferred from the naked eye or palpation [21].

Image-Guided Superficial Radiation Therapy (IGSRT): This therapy utilizes high-resolution dermal ultrasound to visualize the cancer during treatment. When delivered by a multidisciplinary team, IGSRT allows for the precise treatment of Non-Melanoma Skin Cancer (NMSC) with cure rates reported as reaching 99% [24].

5.3 Advanced Optical Techniques

Reflectance Confocal Microscopy (RCM): RCM is a minimally invasive technology that provides high cellular resolution, effectively creating a "virtual biopsy." It has high sensitivity and specificity, making it valuable for diagnosing skin cancer without surgical incision for biopsy [25].

Optical Coherence Tomography (OCT): While offering lower resolution than RCM, OCT is useful for evaluating tumor margins and monitoring treatment response. Both RCM and OCT help reduce the number of unnecessary biopsies [25].

Systemic Imaging: For advanced cases, techniques like PET-CT (Positron Emission Tomography-Computed Tomography) and MRI are used to detect metastasis [21].

5.4 Nanotechnology in Diagnosis

Nanomedicine offers a new frontier in diagnostics. Precisely engineered nanoparticles can be used as contrast agents in imaging, allowing for high-resolution tumor detection. These particles can target tissues via passive or active mechanisms, improving the accuracy of cancer identification [26, 27].

6. Preventive Strategies: A Multi-Faceted Approach

Prevention is the most effective strategy against the rising tide of skin cancer. Measures are categorized into protection against UV radiation, lifestyle modifications, and medical interventions.

6.1 Photoprotection

UV radiation is ubiquitous, and protection is the first line of defense.

Sunscreen: The regular use of broad-spectrum sunscreen is essential. An SPF (Sun Protection Factor) of 30 implies the product blocks approximately 97% of UVB rays. This allows a person to be exposed to the sun three times longer (or more) before burning compared to unprotected skin [28].

Behavioral Measures: The most effective preventive method involves a multi-faceted approach: avoiding the sun during peak intensity hours, seeking shade, and wearing protective apparel (hats, sunglasses, long sleeves). Educational programs promoting these habits are critical, particularly for children [29].

UV Index: Protective measures are recommended whenever the UV index is forecast to be three or higher [28].

Artificial UV: The use of tanning beds and other artificial UV sources to boost tanning is considered an unhealthy action and should be discouraged, potentially by government regulation [28].

6.2 Dietary Phytochemicals and Chemoprevention

Diet plays a significant role in cancer prevention through epigenetics, the manifestation of modified gene expression.

Mechanism: Cancer development can take decades. Dietary phytochemicals are excellent candidates for prevention due to their low toxicity, potent antioxidant properties, and anti-inflammatory effects [30]. They can reverse pro-carcinogenic actions via epigenetic regulation.

Sources: Flavonoids: Quercetin (found in apples and onions); Carotenoids: Beta-carotene and lycopene (found in carrots and tomatoes); Polyphenols: Resveratrol (red grapes) and curcumin (turmeric) [30].

Silymarin and Botanical Agents: Naturally occurring compounds like silymarin and silibinin, as well as substances derived from algae and fungi, are being investigated for their therapeutic potential [31].

6.3 Chemical Peels

A chemical peel is a controlled exfoliation technique using an acid solution to remove dead skin cells.

Therapeutic Use: Beyond cosmetic improvement (treating wrinkles, acne scars), chemical peels are primarily used to treat actinic keratoses, pre-cancerous skin growths. By eliminating abnormal cells in the epidermis, peels can prevent the progression to invasive cancer [32].

Safety: They are well-tolerated and cost-effective, with little evidence of systemic toxicity. They offer an attractive option for "field therapy," treating large areas of sun-damaged skin rather than individual lesions [33, 34].

Table 2: Summary of Preventive Measures

Category	Specific Measures	Mechanism of Protection
UV Protection	• Broad-spectrum Sunscreen (SPF 30+) • Protective clothing & sunglasses • Seeking shade/Avoiding peak hours	Blocks or absorbs UV radiation; prevents direct DNA damage (dimers) and sunburn.
Lifestyle	• Smoking cessation • Regular physical activity • Avoidance of tanning beds	Reduces systemic inflammation and oxidative stress; avoids concentrated UV mutations.
Dietary	• Consumption of antioxidants (Lycopene, Curcumin, Resveratrol) • High intake of fruits/vegetables	Scavenges reactive oxygen species (ROS); epigenetic modulation of tumor suppressors.
Medical	• Chemical Peels • Oral Retinoids (high-risk patients) • Vaccination (HPV, potential melanoma vaccines)	Removes precancerous cells (actinic keratosis); boosts immune surveillance.

7. Therapeutic Management: Current and Emerging Frontiers

The treatment of skin cancer requires a multidisciplinary approach, evolving from simple excision to complex biological therapies.

7.1 Surgical and Local Therapies

Surgery: The mainstay for most localized skin cancers (BCC, SCC, early Melanoma). Mohs surgery is preferred for high-risk areas [10].

Radiation Therapy: Used when surgery is not feasible. Techniques like IGSRT offer high cure rates for NMSC [24].

7.2 Immunotherapy and Vaccines

Immunotherapy works by fortifying or retraining the body's immune system to identify and attack cancer cells.

Immune Checkpoint Inhibitors (ICI): Aggressive cancers evade detection by activating "checkpoints" that shut down immune responses. ICI drugs (e.g., Pembrolizumab, Nivolumab, Ipilimumab) block these proteins (PD-1, CTLA-4), effectively releasing the brakes on the immune system [35, 36].

Impact: These therapies have revolutionized melanoma treatment. For advanced stage IV patients, median survival has improved from six months to approximately six years [37]. Adjuvant nivolumab is now a critical component of treatment to reduce recurrence risk [23].

Vaccines: Preventive vaccines (like those for HPV) protect against virus-induced cancers. Therapeutic vaccines, which train the immune system to attack existing tumors, are showing potential. In adjuvant settings, melanoma vaccines appear to reduce minimal residual disease and relapse [38].

Combination Strategies: A relatively new strategy involves combining ICI with other agents to overcome resistance. For example, targeting the CD30 protein (present on some tumor cells) in combination with anti-PD1 therapy may benefit patients who do not respond to ICI alone [39].

7.3 Nanomedicine and Nanoparticles

Current technologies like conventional chemotherapy have limitations (toxicity, poor penetration). Nanomedicine offers a promising alternative.

Drug Delivery: Nanoparticles (<100 nm) can encapsulate hydrophobic drugs, enzymes, and genes. They facilitate permeation through the skin by interacting with lipid bilayer membranes, allowing for targeted drug retention in the tumor while minimizing systemic side effects [31, 40].

Types: Solid Lipid Nanoparticles & Carbon Nanotubes are used to manage and diagnose both melanoma and non-melanoma cancers [41]. Nanogels represent a new generation of delivery systems combining hydrogels and nanoparticles [42].

Mechanism: Nanocarriers can transport therapeutics via passive or active targeting, enhancing the solubility and stability of chemotherapeutics and overcoming drug resistance [40].

7.4 Targeted and Repurposed Therapies

Targeted Therapy: Drugs that precisely target molecules (proteins/genes) essential for cancer survival. Kinase inhibitors are common for melanoma but face challenges with emerging drug resistance [43].

Transcription Factors: Alternative targets include transcription factors like cyclic AMP-regulatory binding protein, which is overactivated in skin cancer [44].

Drug Repurposing: Given the high cost and toxicity of developing new drugs, repurposing existing drugs (e.g., those approved for other diseases) has emerged as a first-rate alternative for skin cancer management [45].

8. Conclusion and Future Outlook

Skin cancer encompasses a spectrum of diseases ranging from the indolent Basal Cell Carcinoma to the aggressive Merkel Cell Carcinoma and Melanoma. Etiology is deeply rooted in the interaction between UV radiation, a preventable environmental carcinogen, and host genetic factors.

Key Takeaways:

Epidemic Scale: With rising rates globally, particularly in regions like New Zealand and among fair-skinned populations, skin cancer is a priority public health issue [8].

Early Detection is Critical: The high treatability of early-stage disease (95%) contrasts sharply with the lethality of metastatic melanoma, emphasizing the need for advanced diagnostic imaging (Ultrasound, RCM) and public awareness [1, 25].

Paradigm Shift in Treatment: The management of skin cancer has transitioned from a surgical-dominant model to one incorporating advanced immunotherapy and nanomedicine. Immune Checkpoint Inhibitors have extended survival in advanced melanoma from months to years, while nanocarriers promise to deliver these potent drugs with reduced toxicity [31, 37].

Prevention Efficacy: Simple behavioral changes such as sun avoidance, sunscreen use, and protective clothing remain the most potent tools for reducing incidence [28].

The future of skin cancer management lies in the personalization of therapy utilizing molecular biomarkers to tailor treatments (e.g., anti-CD30 combinations) and harnessing the power of the immune system and nanotechnology to achieve durable cures.

List of Abbreviations

BCC: Basal Cell Carcinoma
DNA: Deoxyribonucleic acid
ICI: Immune Checkpoint Inhibitors
IGSRT: Image-Guided Superficial Radiation Therapy
MCC: Merkel Cell Carcinoma
NMSC: Non-Melanoma Skin Cancer
PET-CT: Positron Emission Tomography-Computed Tomography
RCM: Reflectance Confocal Microscopy
RNA: Ribonucleic acid
SCC: Squamous Cell Carcinoma
UV: Ultraviolet

Conflict of Interest

The authors declare no conflict of interest, financial or otherwise.

References

1. Spanos S, Singh N, Laginha BA, *et al*. Measuring the quality of skin cancer management in primary care: A scoping review. Australas J Dermatol 2023; 64(2): 177-93. https://doi.org/10.1111/ajd.14023
2. Steinhoff M, Alam M, Ahmad A, Uddin S, Buddenkotte J. Targeting oncogenic transcription factors in skin malignancies: An update on cancer stemness and therapeutic outcomes. Semin Cancer Biol 2022; 87:98-116. Doi: 10.1016/j.semcancer.2022.11.009. https://pubmed.ncbi.nlm.nih.gov/36372325/
3. Tang X, Yang T, Yu D, Xiong H, Zhang S. Current insights and future perspectives of ultraviolet radiation (UV) exposure: Friends and foes to the skin and beyond the skin. Environ Int 2024; 185:108535. https://www.sciencedirect.com/science/article/pii/S0160412024001211
4. Al-Sadek T, Yusuf N. Ultraviolet Radiation Biological and Medical Implications. Mol Biol 2024;46(3):1924-42. Publ. FEB 24, 2024, PMID: 38534742 Doi: 10.3390/cimb46030126. https://pubmed.ncbi.nlm.nih.gov/38534742/
5. Montano E, Bhatia N, Ostojić J. Biomarkers in Cutaneous Keratinocyte Carcinomas. Dermatol Ther 2024;14(8) 2039-58. https://link.springer.com/article/10.1007/s13555-024-01233-w
6. Wang M, Gao X, Zhang L. Recent global patterns in skin cancer incidence mortality and prevalence. Chin Med J 2024; 138(2): 185-92. doi: 10.1097/CM9.0000000000003416 PMID: 39682020 https://pmc.ncbi.nlm.nih.gov/articles/PMC11745855/
7. Yasvinski D. Melanoma treatment gets better results when it's personalized. 2023, Postmedia News, Published Jun 12, 2023, Last updated Feb 19, 2025. https://www.healthing.ca/skin-cancer/melanoma-immunotherapy
8. Skintel Academic Centre. Why New Zealand has one of the highest cancer rates in the world. 2023. Latest updated October 19, 2023. https;//skintel.co.nz/articles/nz-high-rate-skin-cancer/
9. Morton DL, Essner R, Kirkwood JM, Wollman RC. NIH National Library of Medicine Holland-Frei Cancer Medicine. 2023, 6th edition. History of Melanoma Copyright © 2003, BC Decker Inc. Bookshelf ID: NBK13962. https://www.ncbi.nlm.nih.gov/books/NBK13962/
10. Gentle Cure Blog When Was Skin Cancer First Discovered?)- 2025. Health Professional Version. 2024. Updated 03, 2023. https://www.gentlecure.com/when-was-skin-cancer-first-discovered/
11. Risks and causes of skin cancer. Cancer Research UK. 2023. Last updated Jan 03, 2023.

https://www.cancerresearchuk.org/about-cancer/skin-cancer/risks-causes

12. Causes and Risk Factors for Skin Cancer. Skin and Hair Care. Preventing Skin Cancer.2025. Copyright © 2025 The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved. https://www.hopkinsmedicine.org/health/conditions-and-diseases/causes-and-risk-factors-for-skin-cancer
13. Symanzik C, John SW. Prevention of Occupational Skin Cancer Caused by Solar Ultraviolet Radiation Exposure: Recent Achievements and Perspectives. Dermatol 2024, 4(2), 46-59. Publ. June 6, 2024. https://doi.org/10.3390/dermato4020006
14. Skin Cancer, Overviewed Mayo Clinic Press, 2024-2025 US News and World Report. https://www.mayoclinic.org/diseases-conditions/skin-cancer/symptoms-causes/syc-20377605
15. Vishwas S, Paul SD, Singh D. An Insight on Skin Cancer About Different Targets with Update on Clinical Trials and Investigational Drugs. Curr Drug Deliv 2024; 21(6): 852-869. Doi: 10.2174/1567201820666230726150642. https://pubmed.ncbi.nlm.nih.gov/37496132/
16. Zeb F, Naqeeb H, Osaili T, *et al*. Molecular crosstalk between polyphenols and gut microbiota in cancer prevention. Nutr Res 2024; 124: 21-42. https://doi.org/10.1016/j.nutres.2024.01.012
17. NIH-National Cancer Institute of Genetics of Skin Cancer (PDQ®) Health Professional Version. 2024. Updated: May 09, 2025. https://www.cancer.gov/types/skin/hp/skin-genetics-pdq
18. Canadian Cancer Society. 2025. - non-melanoma Signs and symptoms. Last medical review: July 2024. https://cancer.ca/en/cancer-information/cancer-types/skin-non-melanoma/signs-and-symptoms
19. Trager MH, Geskin LJ, Samie FH, Liu L. Biomarkers in melanoma and non-melanoma skin cancer prevention and risk stratification. Exp Dermatol 2022;31(1):4-12. Publ. 16 May 2020. https://doi.org/10.1111/exd.14114
20. Melanoma-Disease and Conditions. Mayo Clinic. © 1998-2025 Mayo Foundation for Medical Education and Research (MFMER). All rights reserved. https://www.mayoclinic.org/diseases-conditions/melanoma/symptoms-causes/syc-20374884
21. Merkel cell carcinoma. Diseases and conditions. 2025. Mayo clinic. Jan 10, 2025.
22. https://www.mayoclinic.org/diseases-conditions/merkel-cell-carcinoma/symptoms-causes/syc-20351030
23. Lugowska I, Becker JC, Ascierto PA, *et al*. Merkel-cell carcinoma: ESMO–EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up. ESMO Journals 2024;9 (5):102977. May 2024. https://pubmed.ncbi.nlm.nih.gov/38796285/
24. Becke, JC, Stang A, Schrama D, Ugurel S. Merkel Cell Carcinoma: Integrating Epidemiology, Immunology, and Therapeutic Updates. Am J Clin Dermatol 2024; 25(4): 541-57. Doi: 10.1007/s40257-024-00858-z PMID: 38649621. https://pubmed.ncbi.nlm.nih.gov/38649621/
25. Stricker JB, Hopkins J, Farberg AS, Harris PM. Understanding the Importance of Daily Imaging in the Treatment of Non-Melanoma Skin Cancer with Image-Guided Superficial Radiation Therapy. Derme to 2024; 4 (3): 86-96. Publ. Aug 24, 2024. https://doi.org/10.3390/dermato4030010
26. Jung JM, Cho JY, Lee WJ, Chang SE, Lee MW, Won CH. Emerging Minimally Invasive Technologies for the Detection of Skin Cancer. [Palazzo E, Ed.] J Pers Med 2021; 11(10):951. PMID: 34683091 Doi: 10.3390/jpm11100951. https://pubmed.ncbi.nlm.nih.gov/34683091/
27. Adamus-Grabicka AA, Hikisz P, Sikora J. Nanotechnology as a Promising Method in

the Treatment of Skin Cancer. [Bazylinska U, Ed.] Int J Mol Sci 2024;25(4):2165. Publ. Feb 10, 2024. PMID: 38396841 Doi: 10.3390/ijms25042165. https://pubmed.ncbi.nlm.nih.gov/38396841/

28. Wang B, Hu S, Teng Y, *et al*. Current advance of nanotechnology in diagnosis and treatment for malignant tumors. Signal Transduct Target Ther 2024; 9:200. Publ. Aug 12, 2024. https://pubmed.ncbi.nlm.nih.gov/39128942/
29. Garbea C, Forseab A-M, Amarala T, *et al*. Skin cancers are the most frequent cancers in fair-skinned populations, but we can prevent them. Curr Pers 2024; 204. 11407.
30. Alonso-Belmonte C, Montero-Vilchez T, Arias-Santiago S, Buendía-Eisman A. [Translated article Spanish to English] Current State of Skin Cancer Prevention: A Systematic Review 2022 Actas Dermosifiliogr 2022;113(8): T781-T791. Doi: 10.1016/j.ad.2022.04.018. https://www.sciencedirect.com/science/article/pii/S0001731022006251
31. Chou PJ, Mary PR, Ahmad S, et al. Epigenetics of Dietary Phytochemicals in Cancer Prevention Fact or Fiction. Cancer J (US) 2024; 30(5):320-8. DOI: 10.1097/PPO.0000000000000742. https://pubmed.ncbi.nlm.nih.gov/39312452/
32. Chang J, Yu B, Saltzman WM, Girardi M. Nanoparticles as a Therapeutic Delivery System for Skin Cancer Prevention and Treatment. JD Innov 2023; 3(4):100197. Publ.March16, 2023. PMID: 37205301. https://www.sciencedirect.com/science/article/pii/S266702672300019X
33. DeMarco C. Chemical peels Are they safe for cancer patients? 2024. The University of Texas. MD Anderson center. Medically reviewed and Publ. June 22, 2024. https://www.mdanderson.org/cancerwise/chemical-peels--are-they-safe-for-cancer-patients.h00-159698334.html
34. Sidiropoulou P, Gregoriou S, Gregoriou S. Rigopoulos D. Chemical Peels in Skin Cancer: A Review. J Clin Aesthet Dermatol 2020; 13(2):53-7. Publ. Feb 20, 2020, PMID: 32308785. https://pubmed.ncbi.nlm.nih.gov/32308785/
35. Jiang A, Soon SL, Rullan P, *et al*. A Chemical Peels as Field Therapy for Actinic Keratoses: A Systematic Review Systematic Review. Dermatol Surg 2021; 47(10):1343-46. PMID: 34238790. https://pubmed.ncbi.nlm.nih.gov/34238790/
36. Kohnehshahri MK, Sarkesh A, Mohamed Khosroshahi LM, et al. Current status of skin cancers with a focus on immunology and immunotherapy. Cancer Cell International 2023; 23(1)174. Doi: 10.1186/s12935-023-03012-7. https://pubmed.ncbi.nlm.nih.gov/37605149/
37. Mallardo D, Basile D, Vitale MG. Advances in Melanoma and Skin Cancers. Int J Mol Sci. 2025 Feb 21; 26(5):1849. Publ. Feb 21, 2025. https://doi.org/10.3390/ijms26051849
38. Knight A, Karapetyan L, Kirkwood JM. Immunotherapy in Melanoma: Recent Advances and Future Directions. [Berger AC, Ed. Knight] Cancer (Basel) 2023;15(4).110. Doi: 10.3390/cancers15041106. https://pmc.ncbi.nlm.nih.gov/articles/PMC9954703/
39. Pail O, Lin MJ, Anagnostou T, Brown BD, Brody JD. Cancer vaccines and the future of immunotherapy. Lancet 2025; 406 (10499): 189-202. https://doi.org/10.1016/S0140-6736(25)00553-7
40. Amarnath S. New therapy to overcome treatment-resistant skin cancers. eCancer. Publ. June 02, 2025. Newcastle University. https://www.ncl.ac.uk/press/articles/latest/2025/06/newskincancertreatment/
41. Ali MS, Almoyad MAA, Wahab S, et al. Recent advances in lipid-based nanocarriers for advanced skin cancer therapy. Int J Pharm 2025;670: 125203.https://doi.org/10.1016/j.ijpharm.2025.125203
42. Jindal M, Kaur M, Nagpal M, Singh M, Aggarwal G, Dhingra GA. Skin Cancer Management: Current Scenario and Future Perspectives. Curr Drug Saf Publ. 01 Jan 2023, 18(2):143-58. PMID: 35422227.

https://pubmed.ncbi.nlm.nih.gov/35422227/

43. Attama AA., Nnammani PO, Onokala OB, Ugwu AA, Onugwu AL. Nanogels as target drug delivery systems in cancer therapy: A review of the last decade. Front Pharmacol 2022; 13. 2022 https://doi.org/10.3389/fphar.2022.874510
44. Drugs Approved for Skin Cancer, NIH National Cancer Institute 2025, Updated Feb 28, 2025. https://www.cancer.gov/about-cancer/treatment/drugs/skin
45. Nayar JC, Abboud M, Dixon KM. Cyclic AMP regulatory element-binding a novel UV targeted factor in skin cancer. Photochem Photobiol Sci 2024; 23:1209-15. Publ. May 14, 2024. https://pubmed.ncbi.nlm.nih.gov/38743195/
46. Cortés H, Reyes-Hernández OD, Alcalá-Alcalá S, et al. Repurposing of Drug Candidates for Treatment of Skin Cancer. Front Oncol 2021; 10:605714. Publ. Jan 08, 2021. PMID: 40076483. https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2020.605714/full